摘要
目的本研究旨在探讨survivin与bcl-2基因反义寡脱氧核苷酸联合对人乳腺癌裸鼠皮下移植瘤的治疗作用。方法在BALB/c裸鼠上建立MCF-7乳腺癌细胞株模型,然后随机分成阴性对照组和5个实验组[分别为脂质体survivin正义脱氧寡核苷酸(SODN)组、脂质体bcl-2SODN组、脂质体survivin反义寡脱氧核苷酸(ASODN)组、脂质体bcl-2ASODN组、联合反义给药组]。检测裸鼠体重及肿瘤体积变化,计算抑瘤率及肿瘤缩小率。结果给药后,联合反义给药组的肿瘤体积抑瘤率为78.4%,肿瘤重量抑瘤率为75.3%,肿瘤缩小率为41.6%。在给药后,各组裸鼠体重变化无明显统计学差异(P>0.05)。结论survivin与bcl-2基因反义寡核酸联合在体内能明显抑制肿瘤生长。
AIM： To investigate the effects of survivin and bcl-2 combined with ASODN on the treatment of breast cancer xenograft in nude mice. METHODS： The model of xenografts derived from MCF-7 breast cancer cell was established in BALB/c nude mice, then they were randomly divided into a negative control group and 5 experimental groups [ intraperitoneal injection of liposomesurvivin-SODN, liposome- bcl-2-SODN, liposome-survivin-ASODN, liposome- bcl-2-ASODN , combined ASODN ]. The tumor growth inhibitory rate and the tumor volume decreased rate were calculated. RESULTS： Survivin and bcl-2 combined with ASODN exhibited potent tumor growth inhibition. The tumor volume inhibitory rate was 78.4%; the tumor weight inhibitory rate was 75.3% ; the tumor volume decreased rate was 41.6% for combined group post-experiment of the 6 groups, and there was no significant difference on nude mice weight post-experiment. CONCLUSION： Survivin and bcl- 2 combined with ASODN showed potent tumor growth inhibition in vivo.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2006年第10期1164-1167,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
